Merck Prepares for KEYTRUDA Exclusivity Loss Amid Share Price Growth

Pharmaceutical giant Merck & Co. is preparing for the loss of market exclusivity on its key cancer treatment, KEYTRUDA. Despite a recent dip in stock price to $144.71, representing a 1.91% drop from the previous day, shares have gained nearly 11% over the past month.

This growth outperforms the broader market, but analysts remain cautious about Merck's prospects. Luisa Hector has set a price target of $137 for KEYTRUDA, which is below its current price.

Investors are awaiting Merck's upcoming financial report, which is expected to show earnings of $2.27 per share and revenue rising 1.94% to $17.61 billion.